2018 ASH Annual Meeting

The 2018 American Society of Hematology Annual Meeting & Exposition, held at the San Diego Convention Center in San Diego, California, from December 1-4, 2018.

Triplet Regimen Could Replace Standard of Care for Transplant-Ineligible Myeloma

Jason M. Broderick

$Selinexor Combo Sees Activity in Heavily Pretreated Penta-Refractory Myeloma$

Selinexor Combo Sees Activity in Heavily Pretreated Penta-Refractory Myeloma

Wayne Kuznar

Consistent OS Benefit Seen Across Patient Subgroups With Quizartinib in AML

Jason M. Broderick

Risk of Progression Significantly Reduced With Upfront Ibrutinib and Obinutuzumab in CLL/SLL

Gina Columbus

Durable Responses Achieved With Acalabrutinib in MCL

Wayne Kuznar

Early Activity Seen With Anti-BCMA CAR T Cell in Heavily Pretreated Multiple Myeloma

Silas Inman

Key Findings Reviewed From ALCYONE Trial in Myeloma

Maria-Victoria Mateos, MD, PhD

$Promising Results Seen With Ibrutinib Plus Venetoclax Combo in Relapsed/Refractory CLL$

Promising Results Seen With Ibrutinib Plus Venetoclax Combo in Relapsed/Refractory CLL

Wayne Kuznar

Next Page >>

Specialties >>

Partners >>

2018 ASH Annual Meeting

Specialties >>

Partners >>

2018 ASH Annual Meeting

JTT Articles